Golden Ten Data December 27th news, Haier Biological announced that the company is planning to absorb and merge Shanghai Lai Shi through Haier Biological to all shareholders of Shanghai Lai Shi by exchanging shares of A shares of Haier Biological and raising funds for A-share offering. Due to the planning of major asset restructuring matters, the company's securities have been suspended from trading since the opening of the market on December 23, 2024, and the suspension is expected to last no more than 10 trading days. As of the date of this announcement, the company and relevant parties are actively advancing the work related to this transaction.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Haier Biology: Önemli Varlık Yeniden Yapılandırma İşlemleri Planlanıyor
Golden Ten Data December 27th news, Haier Biological announced that the company is planning to absorb and merge Shanghai Lai Shi through Haier Biological to all shareholders of Shanghai Lai Shi by exchanging shares of A shares of Haier Biological and raising funds for A-share offering. Due to the planning of major asset restructuring matters, the company's securities have been suspended from trading since the opening of the market on December 23, 2024, and the suspension is expected to last no more than 10 trading days. As of the date of this announcement, the company and relevant parties are actively advancing the work related to this transaction.